Jan 19, 2021 | AIMS-2-TRIALS News
A world-leading AIMS-2-TRIALS team at the Institut Pasteur (Paris) has developed a secure database to address the needs of the AIMS-2-TRIALS project, ensuring that large, multidisciplinary datasets from participants across Europe are secure, GDPR compliant and easily...
Jan 19, 2021 | AIMS-2-TRIALS News
AIMS-2-TRIALS researchers from King’s College London have revealed that reduced flexible behaviour in autistic people is underpinned by different dominant learning mechanisms across development, and less optimal learning. Background Flexible behaviour is critical for...
Jan 19, 2021 | AIMS-2-TRIALS News
Letters of support now available on the EMA website. The AIMS-2-TRIALS consortium has received feedback (qualification advice) from the European Medicines Agency (EMA) on the further exploration of EEG (electroencephalography) as a potential ‘biomarker’ in autism...
Dec 8, 2020 | AIMS-2-TRIALS News
Over the last decade, researchers have worked hard to identify reliable ways to measure and track the emergence and progression of autism. One promising area of focus has been exploration of how autistic people focus their attention on social cues. Our research In...
Dec 2, 2020 | AIMS-2-TRIALS News
Autism is a condition that varies a lot between individuals, which means that any therapy or treatment is unlikely to be useful for all autistic people. However, most research does not take such differences between autistic individuals into account. Researchers need...
